Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26050074 | 0.86 | ADRB2 (0.48) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL26050020 | 0.86 | ADRB2 (0.55) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL26050057 | 0.81 | ADRB2 (0.55) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL26050055 | 0.81 | ADRB2 (0.50) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL22481135 | 0.81 | ADRB2 (0.54) | ADRB2ADRB1ADRB3 | |
| SCHEMBL23541650 | 0.77 | MEN1 (0.49) | ADRB2SMN1; SMN2ADRB1ADRB3KMT2A | |
| SCHEMBL26050037 | 0.74 | ADRB2 (0.55) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL5442319 | 0.72 | ADRB2 (0.63) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL10717538 | 0.71 | KDM4E (0.90) | ADRB2KDM4EGAASMN1; SMN2TDP1 | |
| SCHEMBL9468414 | 0.71 | KDM4E (0.83) | ADRB2KDM4EGAASMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | CURASEN THERAPEUTICS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308115-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885KDM4E 4707/4885GAA 1088/4885 |
| US-10947196-B2 | Beta adrenergic agonist and methods of using the same | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885KDM4E 4707/4885GAA 1088/4885 |
| US-20230263749-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB2 4/4885KDM4E 2200/4885GAA 876/4885 |
| US-20230157974-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | ADRA2A, SNCA, ADRA1A | ADRB2 4/4885KDM4E 2200/4885GAA 876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.